Combined Use of 18F-FDG PET/CT, DW-MRI, and DCE-MRI in Treatment Response for Preoperative Chemoradiation Therapy in Locally Invasive Rectal Cancers

Gu, Jin; Khong, Pek‐Lan; Wang, Silun; Law, Wai‐Lun; Chan, T. K.; Shek, Tony W. H.; Liu, Rico; Zhang, Jingbo

doi:10.1097/rlu.0b013e318266ce52

Cited by 14 publications

(6 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar results have been shown recently . Although Gu et al reported in their rectal cancer study that neither K trans or ADC values at baseline nor their corresponding changes after 2 weeks of CRT were valuable to differentiate between responders and nonresponders, their study was small in size ( n = 8).…”

Section: Discussionsupporting

confidence: 58%

Early response to chemoradiotherapy for nasopharyngeal carcinoma treatment: Value of dynamic contrast‐enhanced 3.0 T MRI

Zheng

Chen

Liu

et al. 2014

Magnetic Resonance Imaging

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 58%

Early response to chemoradiotherapy for nasopharyngeal carcinoma treatment: Value of dynamic contrast‐enhanced 3.0 T MRI

Zheng

Chen

Liu

et al. 2014

Magnetic Resonance Imaging

View full text Add to dashboard Cite

show abstract

“…Higher baseline K trans and k ep in the responder group were also reported by Tao et al who assessed the response 36 patients with NSCLC to chemo-radiotherapy [38]. Gu et al did not find baseline DCE-MRI parameters useful for the discrimination of responders vs. nonresponders; however, this study as many others operated on small sample sizes ( n = 8; [39]).…”

Section: Discussionsupporting

confidence: 50%

Early Prediction of Treatment Response of Neuroendocrine Hepatic Metastases after Peptide Receptor Radionuclide Therapy with ⁹⁰Y-DOTATOC Using Diffusion Weighted and Dynamic Contrast-Enhanced MRI

Weikert

Maas

Haas

et al. 2019

Contrast Media & Molecular Imaging

View full text Add to dashboard Cite

The purpose of this study was to determine if parameters derived from diffusion-weighted (DW-) and dynamic contrast-enhanced (DCE-) magnetic resonance imaging (MRI) can help to assess early response to peptide receptor radionuclide therapy (PRRT) with 90Y-DOTATOC in neuroendocrine hepatic metastases (NET-HM). Twenty patients (10 male; 10 female; mean age: 59.2 years) with NET-HM were prospectively enrolled in this single-center imaging study. DW-MRI and DCE-MRI studies were performed just before and 48 hours after therapy with 90Y-DOTATOC. Abdominal SPECT/CT was performed 24 hours after therapy. This MRI imaging and therapy session was repeated after a mean interval of 10 weeks. Up to four lesions per patient were evaluated. Response to therapy was evaluated using metastasis sizes at the first and second therapy session as standard for comparison (regressive, stable, and progressive). DW-MRI analysis included the apparent diffusion coefficient (ADC) and parameters related to intravoxel incoherent motion (IVIM), namely, diffusion (D), perfusion fraction (f) and pseudo-diffusion (D∗). DCE-MRI analysis comprised Ktrans, ve and kep. For statistical analysis of group differences, one-way analysis of variance (ANOVA) and appropriate post hoc testing was performed. A total of 51 lesions were evaluated. Seven of 51 lesions (14%) showed size progression, 18/51 (35%) regression, and 26/51 (51%) remained stable. The lesion-to-spleen uptake ratio in SPECT showed a decrease between the two treatment sessions that was significantly stronger in regressive lesions compared with stable (p = 0.013) and progressive lesions (p = 0.021). ANOVA showed significant differences in mean ADC after 48 h (p = 0.026), with higher ADC values for regressive lesions. Regarding IVIM, highest values for D at baseline were seen in regressive lesions (p = 0.023). In DCE-MRI, a statistically significant increase in ve after 10 weeks (p = 0.046) was found in regressive lesions. No differences were observed for the transfer constants Ktrans and kep. Diffusion restriction quantified as ADC was able to differentiate regressive from progressive NET-HMs as early as 48 hours after PRRT. DW-MRI therefore may complement scintigraphy/SPECT for early assessment of response to PRRT. Assessment of perfusion parameters using IVIM and DCE-MRI did not show an additional benefit.

show abstract

“…However, Gu et al . 33 reported in their rectal cancer study that DCE-MRI parameters at baseline were worthless to differentiate between responders and non-responders. These contrary results may due to small sample size ( n = 5–13), different clinical staging of patients, different clinical treatment programs or other mixed factors.…”

Section: Discussionmentioning

confidence: 99%

DCE-MRI Perfusion and Permeability Parameters as predictors of tumor response to CCRT in Patients with locally advanced NSCLC

Tao

Wang

Hui

et al. 2016

Sci Rep

View full text Add to dashboard Cite

In this prospective study, 36 patients with stage III non-small cell lung cancers (NSCLC), who underwent dynamic contrast-enhanced MRI (DCE-MRI) before concurrent chemo-radiotherapy (CCRT) were enrolled. Pharmacokinetic analysis was carried out after non-rigid motion registration. The perfusion parameters [including Blood Flow (BF), Blood Volume (BV), Mean Transit Time (MTT)] and permeability parameters [including endothelial transfer constant (Ktrans), reflux rate (Kep), fractional extravascular extracellular space volume (Ve), fractional plasma volume (Vp)] were calculated, and their relationship with tumor regression was evaluated. The value of these parameters on predicting responders were calculated by receiver operating characteristic (ROC) curve. Multivariate logistic regression analysis was conducted to find the independent variables. Tumor regression rate is negatively correlated with Ve and its standard variation Ve_SD and positively correlated with Ktrans and Kep. Significant differences between responders and non-responders existed in Ktrans, Kep, Ve, Ve_SD, MTT, BV_SD and MTT_SD (P < 0.05). ROC indicated that Ve < 0.24 gave the largest area under curve of 0.865 to predict responders. Multivariate logistic regression analysis also showed Ve was a significant predictor. Baseline perfusion and permeability parameters calculated from DCE-MRI were seen to be a viable tool for predicting the early treatment response after CCRT of NSCLC.

show abstract

Combined Use of 18F-FDG PET/CT, DW-MRI, and DCE-MRI in Treatment Response for Preoperative Chemoradiation Therapy in Locally Invasive Rectal Cancers

Cited by 14 publications

References 8 publications

Early response to chemoradiotherapy for nasopharyngeal carcinoma treatment: Value of dynamic contrast‐enhanced 3.0 T MRI

Early response to chemoradiotherapy for nasopharyngeal carcinoma treatment: Value of dynamic contrast‐enhanced 3.0 T MRI

Early Prediction of Treatment Response of Neuroendocrine Hepatic Metastases after Peptide Receptor Radionuclide Therapy with ⁹⁰Y-DOTATOC Using Diffusion Weighted and Dynamic Contrast-Enhanced MRI

DCE-MRI Perfusion and Permeability Parameters as predictors of tumor response to CCRT in Patients with locally advanced NSCLC

Contact Info

Product

Resources

About

Combined Use of 18F-FDG PET/CT, DW-MRI, and DCE-MRI in Treatment Response for Preoperative Chemoradiation Therapy in Locally Invasive Rectal Cancers

Cited by 14 publications

References 8 publications

Early response to chemoradiotherapy for nasopharyngeal carcinoma treatment: Value of dynamic contrast‐enhanced 3.0 T MRI

Early response to chemoradiotherapy for nasopharyngeal carcinoma treatment: Value of dynamic contrast‐enhanced 3.0 T MRI

Early Prediction of Treatment Response of Neuroendocrine Hepatic Metastases after Peptide Receptor Radionuclide Therapy with 90Y-DOTATOC Using Diffusion Weighted and Dynamic Contrast-Enhanced MRI

DCE-MRI Perfusion and Permeability Parameters as predictors of tumor response to CCRT in Patients with locally advanced NSCLC

Contact Info

Product

Resources

About

Early Prediction of Treatment Response of Neuroendocrine Hepatic Metastases after Peptide Receptor Radionuclide Therapy with ⁹⁰Y-DOTATOC Using Diffusion Weighted and Dynamic Contrast-Enhanced MRI